Physician profile
John Leighton
NPI 1861461162
$2,091.29
in general payments reported to CMS, 2019-2025
23 companies · $504 in 2025
The $504 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.55 · 2021: $11.92 · 2023: $296 · 2024: $1,267 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183 · Consulting Fee: $700 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.82 |
| Consulting Fee | $700.00 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $573.24 | 2024-2025 | Imfinzi, Enhertu |
| Astellas Pharma US INC | $384.53 | 2023-2025 | Vyloy, Xospata |
| Alexion Pharmaceuticals, INC. | $207.64 | 2025 | Ultomiris |
| Sobi, INC | $145.93 | 2024 | |
| Janssen Biotech, INC. | $117.18 | 2024 | Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $88.47 | 2024 | Opdivo |
| Glaxosmithkline, LLC. | $82.24 | 2023-2025 | Jemperli, Zejula, Blenrep |
| Eisai INC. | $66.33 | 2023 | |
| Incyte Corporation | $65.74 | 2023 | Pemazyre |
| Novartis Pharmaceuticals Corporation | $60.47 | 2024-2025 | |
| Pfizer INC. | $39.68 | 2024 | |
| Genentech USA, INC. | $33.54 | 2024 | Ocrevus Zunovo |
| Gilead Sciences, INC. | $32.00 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.61 | 2024 | Ninlaro |
| Amgen INC. | $23.88 | 2023 | Nplate, Vectibix, Xgeva |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $21.80 | 2024 | Kimmtrak |
| Secura Bio, INC. | $20.91 | 2023 | Copiktra |
| Merck Sharp & Dohme LLC | $20.52 | 2023 | Lynparza, Keytruda |
| Deciphera Pharmaceuticals INC. | $17.64 | 2025 | Qinlock, Romvimza |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Pharmacosmos Therapeutics INC. | $16.81 | 2024 | Monoferric |
| Adaptive Biotechnologies Corporation | $15.56 | 2023 | Clonoseq |
| Teva Pharmaceuticals USA, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Leighton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.